Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.

No abstract is available for this paper.

• Publication year

  1985

• Venue

  Therapeutic Drug Monitoring

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1097/00007691-198512000-00021PMID 4082245
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man

  2005cited by this paper
• Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio.

  1985cited by this paper
• Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes

  1984cited by this paper
• Weak binding of 10-hydroxymetabolites of nortriptyline to rat brain muscarinic acetylcholine receptors.

  1984cited by this paper
• Adverse reactions in connection with zimeldine treatment — a review

  1983cited by this paper
• Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation

  1983cited by this paper
• Protecting poor metabolizers, a group at high risk of adverse drug reactions.

  1983cited by this paper
• The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.

  1983cited by this paper
• Nortriptyline metabolism in chronic renal failure: Metabolite elimination

  1982cited by this paper
• E‐ and Z‐10‐hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation

  1981cited by this paper
• Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications.

  1981cited by this paper
• Intraindividual similarity in the metabolism of amitriptyline and chlorimipramine in depressed patients.

  1979cited by this paper
• Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline.

  1979cited by this paper
• Ion-pair liquid chromatography of amitriptyline and metabolites in plasma.

  1978cited by this paper
• Polymorphic hydroxylation of Debrisoquine in man.

  1977cited by this paper
• Genetic control of nortriptyline kinetics in man: a study of relatives of propositi with high plasma concentrations.

  1971cited by this paper
• Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy

  1969cited by this paper
• [APPARENTLY PARADOXICAL MODIFICATION OF PERIPHERAL NORADRENALINE EFFECTS BY SEVERAL THYMOLEPTIC AGENTS].

  1964cited by this paper

• How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?

  2020cites this paper
• Principles of Pharmacogenomics

  2019cites this paper
• Pharmacogenomics in Psychiatric Disorders

  2019cites this paper
• Pharmacokinetics and phenotyping properties of the Basel phenotyping cocktail combination capsule in healthy male adults

  2019cites this paper
• A New Approach to Measure Adherence to Medicines Using Biomarkers and Sensors

  2019cites this paper
• Optimising migraine treatment: from drug-drug interactions to personalized medicine

  2019cites this paper
• Supervised Classification of CYP2D6 Genotype and Metabolizer Phenotype With Postmortem Tramadol-Exposed Finns

  2019cites this paper
• Clinical Pharmacogenomics Of Human Cyp2d6

  2018cites this paper
• Accurate determination of the CYP2D6 (*1/*4)xN genotype by quantitative PCR

  2018cites this paper
• Post-mortem Pharmacogenetics - Citalopram-positive Suicides as a Model Population

  2018cites this paper
• [Is it personalized treatment of dementia based on the CYP2D6 gene polymorphism possible?]

  2018cites this paper
• Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

  2017cites this paper
• Clinical Legal Medicine and Toxicology in Sexual Assaults

  2017cites this paper
• P5 Medicine and Justice

  2017influential citation
• Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways.

  2016cites this paper
• Development, validation and application of the Basel phenotyping cocktail

  2015cites this paper
• Pharmacogenetics: an Emerging Therapeutic Option for Bangladesh

  2015cites this paper
• Addressing phenoconversion: the Achilles' heel of personalized medicine

  2015cites this paper
• The impact of genetics, environmental, and geographical factors on inter-individual and inter-ethnic differences in CYP2C9-catalysed drug metabolism

  2015cites this paper
• Implementation of pharmacogenetics in evidence-based medicine: Toward advancing personalized medicine

  2014cites this paper
• CYP2D6 : clinical implications in neuropsychiatry

  2014cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic

  2013cites this paper
• Principles of pharmacogenomics: Pharmacokinetic, pharmacodynamic, and clinical implications

  2013cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

  2013cites this paper
• Supplement to: Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

  2013cites this paper
• The AmpliChip™ CYP450 Genotyping Test

  2012cites this paper
• Chapter 13 – Clinical Pharmacogenetics

  2012cites this paper
• Pharmacogenetics in Drug Metabolism: Role of Phase I Enzymes

  2012cites this paper
• Genetic polymorphism of drug metabolizing enzymes in the Shona and the San in Zimbabwe and the clinical impact of CYP2D6 polymorphism on safety in the use of psychotropics

  2012cites this paper
• Pharmacogenomics of CYP 2 D 6 : Molecular Genetics , Interethnic Differences and Clinical Importance

  2012cites this paper
• Psychiatric pharmacogenomics in pediatric psychopharmacology.

  2012cites this paper
• Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance.

  2012cites this paper
• Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs.

  2011cites this paper
• Pharmacogenetics and Gender Association with Psychotic Episodes on Nortriptyline Lower Doses: Patient Cases

  2011cites this paper
• Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions

  2011cites this paper
• Translating pharmacogenetics to primary care

  2011cites this paper
• disorder: Systematic review selective serotonin reuptake inhibitors in major depressive Dose escalation for insufficient response to standard-dose

  2011cites this paper
• Pharmacogenetics of Antidepressants

  2010cites this paper
• Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.

  2010cites this paper
• Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9

  2010cites this paper
• Pharmacogenetics in medico-legal context.

  2010cites this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cites this paper
• CNVs of human genes and their implication in pharmacogenetics

  2009cites this paper
• Pharmacokinetic / pharmacodynamic impact of genetic polymorphism of drug metabolizing enzymes

  2009cites this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cites this paper
• Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study

  2009cites this paper
• Dose-escalation in the picture : pharmacological and imaging studies in depression

  2008cites this paper
• A survey of the personalized medicine landscape

  2008cites this paper
• Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring

  2008cites this paper
• Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy.

  2007cites this paper
• CHAPTER 13 – Clinical Pharmacogenetics

  2007cites this paper
• The effect of single-dose tramadol on oxycodone clearance.

  2007cites this paper
• Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.

  2007cites this paper
• Genetic polymorphism in CYP2D6 and cardiovascular drugs

  2006cites this paper
• Clinical Pharmacogenomics of Drug Metabolizing Enzymes and its Clinical Application

  2006cites this paper
• Pharmacogenetics of cytochromes P450 in tropical medicine.

  2006cites this paper
• The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants

  2006cites this paper
• Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance

  2006cites this paper
• Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder

  2006cites this paper
• Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

  2006cites this paper
• Pharmacogenetics of Drug Metabolism: Two Clinically Important Polymorphic Enzymes, CYP2D6 and TPMT

  2005cites this paper
• The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.

  2005cites this paper
• Pharmacogenomics and its potential impact on drug and formulation development.

  2005cites this paper
• INTERPRETATION OF POSTMORTEM TOXICOLOGY RESULTS Pharmacogenetics and Drug-Alcohol Interaction

  2005cites this paper
• Monoaminergic‐based Pharmacotherapy for Depression

  2005cites this paper
• Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.

  2005cites this paper
• TOXICOLOGY RESULTS Pharmacogenetics and Drug-Alcohol Interaction

  2005cites this paper
• [Pharmacogenomics: the quest for individualized therapy].

  2004cites this paper
• Clinical significance of the sparteine/debrisoquine oxidation polymorphism

  2004cites this paper
• Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics.

  2004cites this paper
• A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study.

  2004cites this paper
• Pharmacogenetics – five decades of therapeutic lessons from genetic diversity

  2004cites this paper
• Pharmacogenetics: ethical problems and solutions

  2004cites this paper
• Oxidative polymorphism of dextromethorphan in a Burundi population

  2004cites this paper
• Neurobiological differences on populational level.

  2004cites this paper
• Glucuronidation enzymes, genes and psychiatry.

  2003cites this paper
• Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.

  2003cites this paper
• Genes, disease and medicine.

  2003cites this paper
• Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

  2003cites this paper
• Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine

  2003cites this paper
• Regulatory aspects of pharmacogenetics and pharmacogenomics

  2003cites this paper
• Characteristics of cytochrome P450-catalysed drug metabolism with focus on a black Tanzanian population

  2003cites this paper
• Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication

  2003cites this paper
• Potential use of olanzapine in treatment of substance dependence disorders.

  2003cites this paper
• Pharmacogenetics of cytochrome P 4502 D 6 : genetic background and clinical implication

  2003cites this paper
• Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19.

  2003cites this paper
• Pharmacokinetics of Antidepressants and Lithium

  2003cites this paper
• Therapy with Antidepressants: Pharmacogenetic Aspects

  2002cites this paper
• Clinical relevance of the CYP2D6 polymorphism for the treatment of psychiatric disorders

  2002cites this paper
• How the pharmacogenetics of cytochrome P450 enzymes may affect prescribing.

  2002cites this paper
• 37 PHARMACOGENOMICS AND PERSONALIZED THERAPEUTICS IN PSYCHIATRY

  2002cites this paper
• Pharmacogenetics: A Principle for the Personalized Pharmacotherapy

  2002cites this paper
• Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

  2002cites this paper
• Genetic polymorphisms of CYP2D6 in Chinese mainland.

  2002cites this paper
• Excessive antipsychotic dosing in 2 U.S. State hospitals.

  2002cites this paper
• CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages

  2001cites this paper
• Pharmacogenetics

  2001cites this paper
• Codeine phosphate in paediatric medicine.

  2001cites this paper
• CYP1A2 Activity as Measured by a Caffeine Test Predicts Clozapine and Active Metabolite Norclozapine Steady-State Concentration in Patients With Schizophrenia

  2001cites this paper
• CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.

  2001cites this paper